- Shares of Cubist Pharmaceuticals (CBST +4.9%) are up handsomely again today, adding to gains posted Wednesday following the company's acquisitions of Trius and Optimer. (previous coverage)
- Aegis Capital upgrades CBST to Buy.
- Jefferies ups the price target on CBST to $70 from $64. Acquisitions should increase earnings in FY14, 15, and 16 by 7%, 13%, and 17% respectively, analyst Eun Yang says.
Cubist continues to rally
Aug 1 2013, 10:59 ET